Fig. 2: Differences in gene expression and clinical outcomes by timing of WGD. | Nature Communications

Fig. 2: Differences in gene expression and clinical outcomes by timing of WGD.

From: Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

Fig. 2

a Hierarchical clustering of Hallmark pathway enrichment scores in the discovery ICGC cohort. n = 79. Heatmap is annotated by timing of whole genome duplication (WGD), clinical response to first line therapy and molecular subtype (C1,C2,C4,C5). b Two-sided Kaplan–Meier analysis of overall survival (top) and progression free survival (bottom) by presence and timing of WGD in 352 patients (ICGC and TCGA cohorts combined). c Top: Representative image of core stained with anti-HLA DR + DP + DQ for each WGD category; scale bar is 200 μm. Bottom: Waffle plots depicting immunohistochemistry (IHC) results, coloured by zero (yellow) versus any (lilac) staining with anti-HLA DR + DP + DQ, separated by WGD status. Early WGD n = 23 cores; Late WGD n = 49 cores; No WGD n = 37 cores. Source data are provided as a Source Data file.

Back to article page